Astellas Vir Partnership Advances Prostate Cancer Program
Astellas Vir partnership reshapes VIR-5500, delivering $335 million upfront and shifting development cost, commercialization rights and milestone exposure.
KEY TAKEAWAYS
- Deal provides Vir $335 million upfront and near-term proceeds.
- Astellas will fund 60% of development costs; Vir 40%.
- Astellas holds exclusive ex-U.S. commercialization; U.S. profits split 50/50.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Astellas Pharma and Vir Biotechnology announced on February 23, 2026, a global collaboration to co-develop and co-commercialize VIR-5500, a bispecific PSMA T-cell engager for advanced prostate cancer. The deal shifts development costs and regional commercial rights between the companies, with closing contingent on Hart-Scott-Rodino clearance.
Deal Terms and Development Rights
Vir will receive $335 million upfront and near-term payments, including $240 million in cash, a $75 million equity investment priced at a 50% premium to the 30-day volume-weighted average price as of February 19, 2026, and a $20 million manufacturing technology-transfer milestone. The agreement also includes up to $1.37 billion in development, regulatory, and sales milestones, plus tiered double-digit royalties on net sales outside the U.S.
Development costs will be split 60% to Astellas and 40% to Vir. Astellas holds exclusive commercialization rights outside the U.S., while in the U.S., profits and losses will be shared equally. Vir retains an option to co-promote domestically. Under Vir’s existing PRO-XTEN licensing agreement, it must share a portion of collaboration proceeds with Sanofi.
Vir’s chief executive, Marianne De Backer, said the collaboration will accelerate VIR-5500’s development to potentially benefit more prostate cancer patients.
Clinical Results and Development Timeline
VIR-5500 is a bispecific T-cell engager targeting PSMA and CD3, employing PRO-XTEN dual-masking technology designed to remain inactive until reaching the tumor microenvironment. The program is in a Phase 1 trial (NCT05997615).
An SEC filing disclosed updated Phase 1 data from higher-dose cohorts (≥3,000 µg/kg every three weeks), showing a PSA50 response rate of 82% (14 of 17 evaluable patients), a PSA90 rate of 53% (9 of 17), and an objective response rate of 45% (5 of 11; four confirmed, one unconfirmed). Grade 3 or higher treatment-related adverse events occurred in 12% of patients across all dose cohorts (7 of 59), with no dose-limiting toxicities observed.
The collaboration targets advanced metastatic castration-resistant prostate cancer, a condition with a five-year survival rate near 30% and limited treatment options for patients who develop therapeutic resistance.
Updated Phase 1 results will be presented at the ASCO Genitourinary Cancers Symposium on February 26, 2026. The companies plan to start Phase 1 dose expansions in the second quarter of 2026, including a late-line monotherapy cohort for metastatic castration-resistant prostate cancer, an early-line combination cohort with enzalutamide (Xtandi), and a new metastatic hormone-sensitive cohort. They aim to enter Phase 3 in 2027. Vir will oversee Phase 1 until responsibility transitions to Astellas.
